What was the primary driver of the sales increase in the first quarter of 2019?

The primary drivers for the 8.5% consolidated net sales increase were higher unit volumes across several product lines, including neurotechnology, instruments, knees, hips, medical, and endoscopy products. Acquisitions also contributed to the growth, particularly in the Neurotechnology and Spine segment.

Why did Net Earnings decrease year-over-year despite sales growth?

The decrease in Net Earnings from $443 million to $412 million was influenced by several factors. These include higher research, development, and engineering expenses, increased selling, general, and administrative expenses, recall charges, and a rise in amortization of intangible assets primarily due to recent acquisitions. Additionally, a lower effective tax rate in the prior year due to a large tax benefit impacted the comparison.

How did Stryker's debt management perform in the first quarter?

Stryker actively managed its debt by repaying $500 million in senior unsecured notes in January and $750 million in March 2019, totaling $1.341 billion in debt reduction. This contributed to a significant decrease in long-term debt and an increase in cash used by financing activities.

What is the significance of the increase in international cash holdings?

The company's cash and cash equivalents held outside the United States increased from 25% to 47% of the total holdings. This strategic shift suggests an intention to utilize these funds for global expansion, including organic growth initiatives and potential future acquisitions in international markets.

SYK 10-Q Quarterly Report Q1 FY2019 — Revenue, Net Income, EPS

Summary

Stryker Corporation's first quarter 2019 results demonstrate continued top-line growth, with consolidated net sales increasing by 8.5% to $3.516 billion, driven by strong performance across its MedSurg and Neurotechnology and Spine segments. Despite an increase in operating expenses, particularly R&D and SG&A, the company reported a slight decrease in net earnings to $412 million ($1.09 per diluted share) compared to $443 million ($1.16 per diluted share) in the prior year, primarily impacted by higher amortization of intangibles and recall charges. Key strategic moves include two acquisitions totaling $180 million in the quarter, enhancing its product portfolio, and significant debt repayment, reducing long-term debt by $1.341 billion. While GAAP net earnings saw a decrease, adjusted net earnings per diluted share grew by 11.9%, highlighting the company's focus on operational efficiencies and strategic growth initiatives. Investors should note the increase in international cash holdings, signaling potential for future investments and expansion.

Financial Highlights

51 data points

Beta

Revenue

$3.52B

0.6% Gross Margin

Net Income

$412.00M

0.1% Net Margin

EPS (Diluted)

$1.09

Total Assets

$25.94B

Cash & Equivalents

$1.67B

Free Cash Flow

$191.00M

Financial Statements

Beta

Revenue	$3.52B
Cost of Revenue	$1.23B
Gross Profit	$2.28B
R&D Expenses	$225.00M
SG&A Expenses	$1.40B
Operating Expenses	$1.75B
Operating Income	$528.00M
Net Income	$412.00M
EPS (Basic)	$1.10
EPS (Diluted)	$1.09
Shares Outstanding (Basic)	373.30M
Shares Outstanding (Diluted)	379.30M

Key Highlights

1Consolidated net sales grew 8.5% year-over-year to $3.516 billion, with constant currency growth of 10.6%.
2Neurotechnology and Spine segment showed robust growth of 20.7% (23.2% in constant currency), boosted by acquisitions and increased shipments.
3The company repaid $1.341 billion of debt in the first quarter, strengthening its balance sheet.
4GAAP Net Earnings decreased to $412 million from $443 million year-over-year, with diluted EPS falling to $1.09 from $1.16.
5Adjusted Net Earnings per Diluted Share increased by 11.9% to $1.88, indicating strong underlying operational performance.
6Two acquisitions were completed for $180 million, furthering the company's growth strategy.
7Cash and cash equivalents decreased significantly from $3.616 billion to $1.674 billion, largely due to debt repayments and share repurchases.

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions